Definition and epidemiology
COPD is a common, preventable, and treatable disease characterized by persistent respiratory symptoms and airflow limitation due to airway and/or alveolar abnormalities usually caused by significant exposure to noxious particles or gases. The airflow limitation is not fully reversible and is typically progressive.
COPD affects approximately 10-15% of adults over 40 years in developed countries. It is the third leading cause of death globally, responsible for over 3 million deaths annually. Prevalence increases with age and smoking intensity. Men historically had higher rates, but increasing tobacco use among women has equalized prevalence in many countries.
The disease encompasses two main phenotypes that often coexist: chronic bronchitis (clinically defined as productive cough for at least 3 months per year for 2 consecutive years) and emphysema (pathologically defined as permanent destructive enlargement of airspaces distal to terminal bronchioles). Most patients exhibit features of both.
- COPD diagnosis requires post-bronchodilator FEV₁/FVC <0.70 on spirometry
- Smoking cessation is the only intervention proven to slow FEV₁ decline
- Centrilobular emphysema affects upper lobes and is caused by smoking; panacinar affects lower lobes and is seen in alpha-1 antitrypsin deficiency
- Long-term oxygen therapy (≥15 hrs/day) improves survival in chronic hypoxemia (PaO₂ ≤55 mmHg or SpO₂ ≤88%)
- Inhaled corticosteroids are not first-line; add only if eosinophils ≥300 and frequent exacerbations
- Acute exacerbations are treated with increased bronchodilators, 5 days of systemic corticosteroids, and antibiotics if purulent sputum
- Alpha-1 antitrypsin deficiency causes early-onset, lower-lobe emphysema; screen patients <45 years or non-smokers
- BODE index (BMI, Obstruction, Dyspnea, Exercise) predicts mortality better than FEV₁ alone
Etiology and risk factors
Tobacco smoke is the predominant risk factor, accounting for 85-90% of COPD cases in developed countries. Risk increases with pack-years (packs per day × years smoked), with significant risk typically appearing after 20+ pack-years. Only 15-20% of smokers develop clinically significant COPD, suggesting genetic susceptibility.
Other risk factors:
- Occupational exposures: coal dust, silica, cadmium, welding fumes, organic dusts
- Indoor air pollution: biomass fuel combustion for cooking/heating (major cause in developing countries)
- Outdoor air pollution: particulate matter, ozone
- Alpha-1 antitrypsin (AAT) deficiency: genetic disorder causing early-onset emphysema, especially in lower lobes; suspect in patients <45 years or non-smokers with COPD
- Childhood factors: low birth weight, childhood respiratory infections, impaired lung growth
- Recurrent respiratory infections in adulthood
- Socioeconomic status: poverty correlates with higher COPD risk
Passive smoking exposure also increases COPD risk. Cannabis smoking is an emerging risk factor. Genetic polymorphisms beyond AAT deficiency likely influence susceptibility but are not routinely tested.
Pathophysiology
COPD results from chronic inflammation of airways, lung parenchyma, and pulmonary vasculature in response to inhaled noxious particles.
Chronic bronchitis
Chronic irritation causes hypertrophy and hyperplasia of mucus-secreting glands in bronchi (Reid index >0.5, measuring gland:wall thickness ratio). Increased mucus production, ciliary dysfunction, and airway inflammation lead to chronic productive cough. Small airway fibrosis and mucus plugging cause airflow obstruction. Neutrophils, macrophages, and CD8+ T lymphocytes predominate in airways.
Emphysema
Imbalance between proteases (elastase, matrix metalloproteinases) and antiproteases (alpha-1 antitrypsin, tissue inhibitors) leads to destruction of alveolar walls and loss of elastic recoil. Loss of radial traction causes small airway collapse during expiration, trapping air (dynamic hyperinflation). Two main types:
- Centrilobular (centriacinar): destroys respiratory bronchioles in upper lobes; strongly associated with smoking
- Panacinar: uniformly destroys entire acinus; associated with AAT deficiency, affects lower lobes
Systemic effects
Chronic hypoxemia triggers polycythemia and pulmonary vasoconstriction. Pulmonary hypertension develops from vascular remodeling, hypoxic vasoconstriction, and loss of capillary bed. Chronic inflammation produces systemic effects including skeletal muscle wasting, cardiovascular disease, osteoporosis, and depression.
V/Q mismatch causes hypoxemia. Hyperinflation flattens the diaphragm, reducing mechanical efficiency and increasing work of breathing. CO₂ retention occurs in advanced disease when compensatory mechanisms fail.
Clinical features
COPD typically presents insidiously in the fifth to seventh decade with progressive symptoms.
Symptoms
- Dyspnea: progressive, persistent, worse with exercise; the most common reason patients seek care
- Chronic cough: may be intermittent initially, often productive
- Sputum production: mucoid, becomes purulent during exacerbations
- Wheezing and chest tightness
- Exercise intolerance and fatigue
Physical examination
Early disease may show no abnormalities. Signs emerge as disease progresses:
- Inspection: barrel chest (increased anteroposterior diameter), use of accessory muscles, pursed-lip breathing, prolonged expiratory phase, paradoxical inward movement of lower rib cage (Hoover sign)
- Percussion: hyperresonance, decreased diaphragm excursion
- Auscultation: decreased breath sounds, expiratory wheezes, distant heart sounds
- Advanced disease: cyanosis, cachexia, peripheral edema (cor pulmonale)
Clinical phenotypes
Historically described as "pink puffers" (emphysema-predominant: dyspneic, thin, minimal cough) versus "blue bloaters" (chronic bronchitis-predominant: cyanotic, obese, productive cough, cor pulmonale). Most patients show mixed features, and these terms are not used in modern classification.
Exacerbations
Acute worsening of respiratory symptoms beyond normal day-to-day variation, requiring change in medication. Triggered by respiratory infections (viral or bacterial), air pollution, or unknown factors. Features include increased dyspnea, cough, sputum volume/purulence, wheezing, chest tightness, and sometimes fever.
Diagnosis
Diagnosis requires clinical suspicion plus spirometric confirmation of airflow obstruction.
Spirometry
Essential for diagnosis. Perform post-bronchodilator testing (after inhaled short-acting beta-agonist):
- FEV₁/FVC <0.70 confirms airflow obstruction (GOLD criteria)
- FEV₁ percentage predicted determines severity:
- GOLD 1 (mild): FEV₁ ≥80% predicted
- GOLD 2 (moderate): 50% ≤ FEV₁ <80%
- GOLD 3 (severe): 30% ≤ FEV₁ <50%
- GOLD 4 (very severe): FEV₁ <30%
Reduced FEV₁/FVC ratio with <12% or <200 mL improvement after bronchodilator distinguishes COPD from asthma. Total lung capacity (TLC), functional residual capacity (FRC), and residual volume (RV) are increased; diffusing capacity (DLCO) is decreased in emphysema.
Laboratory tests
- Complete blood count: polycythemia indicates chronic hypoxemia
- Alpha-1 antitrypsin level: screen in patients <45 years, non-smokers, family history, or basilar-predominant emphysema
- Arterial blood gas: assess hypoxemia, hypercapnia, and acid-base status in severe disease or exacerbations
Imaging
Chest X-ray may show hyperinflation (flattened diaphragms, increased retrosternal airspace), hyperlucent lung fields, bullae, and enlarged pulmonary arteries. Often normal in early disease.
Chest CT (high-resolution) better characterizes emphysema distribution and severity, identifies bullae, and excludes other pathology. Not routinely required but useful for surgical planning or uncertain diagnosis.
Other tests
- Pulse oximetry: screen for hypoxemia
- Six-minute walk test: assess functional capacity and desaturation
- Electrocardiogram and echocardiogram: evaluate for pulmonary hypertension and cor pulmonale in advanced disease
Diagnostic criteria
Consider COPD in any patient with dyspnea, chronic cough/sputum, and risk factor exposure (especially smoking). Confirm with post-bronchodilator FEV₁/FVC <0.70. The fixed ratio may overdiagnose COPD in elderly patients and underdiagnose in younger patients, but remains the standard criterion.
Differential diagnosis
Asthma
Usually begins in childhood, symptoms vary day-to-day, nocturnal/early-morning symptoms common, allergic triggers, family history, significant bronchodilator reversibility (>12% and >200 mL FEV₁ improvement), normal spirometry between exacerbations. Asthma-COPD overlap (ACO) exists when features of both are present.
Congestive heart failure
Dyspnea with exertion and orthopnea, basilar crackles, peripheral edema, elevated jugular venous pressure, cardiomegaly on imaging, elevated BNP, preserved FEV₁/FVC ratio. May coexist with COPD.
Bronchiectasis
Large volumes of purulent sputum, recurrent infections, coarse crackles, clubbing in some cases. CT shows bronchial dilation and wall thickening. Can complicate COPD.
Interstitial lung disease
Dry cough, fine inspiratory crackles, clubbing, restrictive pattern on spirometry (decreased TLC, normal/increased FEV₁/FVC), reduced DLCO, reticular infiltrates on imaging.
Tuberculosis
Chronic cough, fever, night sweats, weight loss, hemoptysis, upper lobe cavitary infiltrates. Endemic area exposure. Sputum acid-fast bacilli.
Lung cancer
Weight loss, hemoptysis, chest pain, mass or nodule on imaging. COPD patients have increased lung cancer risk; maintain surveillance.
Obliterative bronchiolitis
Young patient, history of toxic exposure, transplant, or rheumatologic disease. Fixed obstruction with mosaic attenuation on CT.
Alpha-1 antitrypsin deficiency
Early-onset emphysema (<45 years), basilar-predominant distribution, minimal smoking history or non-smoker, family history, liver disease. Confirm with AAT level and phenotyping.
Management
Goals include symptom relief, improved exercise tolerance, reduced exacerbation frequency, and slowed disease progression. Management is stepwise based on symptoms and exacerbation history.
Non-pharmacological
Smoking cessation is the single most effective intervention to slow disease progression. Offer counseling, behavioral support, and pharmacotherapy (nicotine replacement, varenicline, or bupropion).
Vaccinations: annual influenza vaccine, pneumococcal vaccine (PCV15 or PCV20, or PPSV23), COVID-19 vaccination, pertussis booster.
Pulmonary rehabilitation: supervised exercise training, education, and nutritional counseling. Improves symptoms, quality of life, and exercise capacity. Indicated for symptomatic patients (mMRC ≥1 or CAT ≥10).
Oxygen therapy: long-term (≥15 hours/day) improves survival in patients with chronic hypoxemia (PaO₂ ≤55 mmHg or SpO₂ ≤88%, or PaO₂ 56-59 mmHg with cor pulmonale or polycythemia).
Nutritional support: address cachexia in underweight patients, weight reduction in obese patients.
Pharmacological
Bronchodilators are central to symptom management:
- Long-acting muscarinic antagonists (LAMA): tiotropium, glycopyrronium, umeclidinium, aclidinium
- Long-acting beta-2 agonists (LABA): salmeterol, formoterol, indacaterol, vilanterol, olodaterol
- Short-acting bronchodilators: albuterol (SABA), ipratropium (SAMA) for rescue use
Initial therapy for symptomatic COPD:
- Dyspnea without exacerbations: LAMA or LABA monotherapy
- Dyspnea with exacerbations: LAMA + LABA combination
Inhaled corticosteroids (ICS): fluticasone, budesonide, beclomethasone. Add to LABA or LAMA+LABA in patients with:
- Eosinophil count ≥300 cells/μL and ≥2 exacerbations or ≥1 hospitalization per year
- History of asthma-COPD overlap
ICS increase pneumonia risk and should not be used as monotherapy or first-line in COPD.
Phosphodiesterase-4 inhibitor: roflumilast reduces exacerbations in severe COPD with chronic bronchitis phenotype and frequent exacerbations despite bronchodilators. Side effects include diarrhea and weight loss.
Systemic corticosteroids and antibiotics for acute exacerbations. Corticosteroids (e.g., prednisone) typically for 5 days. Antibiotics if increased sputum purulence or severe exacerbation.
Mucolytics (N-acetylcysteine, carbocysteine) may reduce exacerbations in select patients, but evidence is limited.
Interventional and surgical
Lung volume reduction surgery (LVRS): resection of emphysematous lung improves lung mechanics. Benefits patients with upper-lobe predominant emphysema and low exercise capacity. Mortality risk limits use.
Endobronchial valve placement: minimally invasive alternative to LVRS for select patients with severe emphysema and absent collateral ventilation.
Bullectomy: resection of giant bullae compressing functional lung.
Lung transplantation: consider in very severe COPD with poor quality of life despite maximal therapy, typically FEV₁ <25% predicted.
Exacerbation management
- Increase short-acting bronchodilator frequency
- Systemic corticosteroids (e.g., prednisone for 5 days)
- Antibiotics if purulent sputum or severe (amoxicillin-clavulanate, doxycycline, respiratory fluoroquinolone, or macrolide based on local resistance)
- Oxygen to maintain SpO₂ 88-92%
- Non-invasive ventilation (BiPAP) for acute respiratory failure with pH 7.25-7.35
- Intubation and mechanical ventilation if NIV fails or contraindicated
Management approach by GOLD group
Current GOLD guidelines use symptom burden (mMRC or CAT score) and exacerbation history to guide therapy, moving away from purely FEV₁-based classification for treatment decisions.
Complications and prognosis
Complications
Acute exacerbations: most common complication, accelerate lung function decline, increase mortality risk, and reduce quality of life. Hospitalization for exacerbation carries 10% in-hospital mortality.
Respiratory failure: hypoxemic or hypercapnic. May require mechanical ventilation. Chronic hypercapnia with compensatory metabolic alkalosis indicates advanced disease.
Cor pulmonale: right ventricular hypertrophy and failure secondary to pulmonary hypertension. Manifests as peripheral edema, hepatomegaly, elevated jugular venous pressure.
Pneumonia: increased risk due to impaired mucociliary clearance and altered immune function.
Pneumothorax: spontaneous from ruptured bullae, especially in emphysema.
Pulmonary hypertension: occurs in advanced disease; mean pulmonary artery pressure >20 mmHg.
Lung cancer: smoking and chronic inflammation increase risk. COPD patients have 2-6 fold increased lung cancer risk versus smokers without COPD.
Systemic manifestations: cachexia, skeletal muscle weakness, osteoporosis, depression, anxiety, cardiovascular disease, metabolic syndrome.
Prognosis
COPD is progressive and incurable but manageable. Prognosis varies widely depending on severity, exacerbation frequency, comorbidities, and continued smoking.
FEV₁ predicts mortality: 5-year survival approximately 80% for mild COPD, 60% for moderate, 40% for severe, and 25% for very severe disease. However, FEV₁ alone is inadequate; multidimensional indices perform better.
BODE index (Body mass index, Obstruction, Dyspnea, Exercise capacity) better predicts mortality than FEV₁ alone.
Smoking cessation at any stage slows FEV₁ decline to near-normal rates and improves survival.
Exacerbation frequency predicts mortality. Frequent exacerbators (≥2/year) have worse outcomes.
Comorbidities (cardiovascular disease, lung cancer, osteoporosis, diabetes) significantly impact outcomes and mortality.
Median survival after diagnosis of severe COPD is approximately 5-10 years, but substantial variability exists. Most COPD patients die from cardiovascular disease, lung cancer, or respiratory failure. Advance care planning and palliative care integration are important in advanced disease.
For causes of COPD, think SMOKER: Smoking, Mining/occupational dusts, Outdoor/indoor air pollution, Key enzyme deficiency (alpha-1 antitrypsin), Early-life factors, Recurrent infections
Practice questions
1. A 62-year-old man with a 40 pack-year smoking history presents with progressive dyspnea and chronic productive cough for 2 years. He uses accessory muscles to breathe. Examination reveals a barrel chest, decreased breath sounds, and prolonged expiration. Chest X-ray shows hyperinflation with flattened diaphragms. Spirometry after bronchodilator shows FEV₁ 55% predicted and FEV₁/FVC 0.62. Which of the following is the most appropriate next step in management?
2. A 48-year-old non-smoking woman presents with progressive dyspnea for 3 years. She has no occupational exposures. Her brother has similar symptoms. Examination shows barrel chest and decreased breath sounds at the lung bases. Chest CT reveals basilar-predominant emphysema. Spirometry shows FEV₁/FVC 0.58. Which of the following is the most likely diagnosis?
3. A 70-year-old man with severe COPD (FEV₁ 35% predicted) presents to the emergency department with increased dyspnea, purulent sputum, and fever for 2 days. He is using accessory muscles and has decreased breath sounds with scattered wheezes. Oxygen saturation is 86% on room air. Arterial blood gas on 2L oxygen shows pH 7.32, PaCO₂ 58 mmHg, PaO₂ 58 mmHg, HCO₃⁻ 29 mEq/L. Which of the following is the most appropriate management?
Frequently asked questions
What causes COPD?
Tobacco smoking causes 85-90% of COPD cases. Other causes include occupational dust exposure (coal, silica, cadmium), biomass fuel smoke from indoor cooking, outdoor air pollution, alpha-1 antitrypsin deficiency (genetic), childhood respiratory infections, and low birth weight. Passive smoking also increases risk. The disease results from chronic inflammation and damage to airways and lung tissue from inhaled irritants.
What are the first symptoms of COPD?
The earliest symptom is typically a chronic productive cough, often dismissed as 'smoker's cough.' Progressive dyspnea on exertion develops next, initially only with strenuous activity but gradually worsening to affect daily activities. Wheezing and chest tightness may occur. Symptoms develop insidiously over years, and patients often adapt their activity level, delaying medical attention until disease is moderate or severe. Symptoms worsen during acute exacerbations.
How is COPD diagnosed?
COPD is diagnosed by spirometry showing persistent airflow obstruction. After administering a bronchodilator, an FEV₁/FVC ratio <0.70 confirms the diagnosis. Suspect COPD in patients over 40 with dyspnea, chronic cough or sputum, and exposure to risk factors (especially smoking). Chest X-ray may show hyperinflation but is often normal early. FEV₁ percentage predicted determines severity (mild ≥80%, moderate 50-79%, severe 30-49%, very severe <30%).
Is COPD curable?
No, COPD is not curable, and airflow limitation is irreversible. However, it is treatable and manageable. Smoking cessation is the most effective intervention to slow disease progression. Bronchodilators improve symptoms and quality of life. Pulmonary rehabilitation enhances exercise capacity. Long-term oxygen therapy prolongs survival in chronic hypoxemia. Vaccinations and treatment of exacerbations reduce complications. With proper management, many patients maintain reasonable quality of life for years.
COPD vs asthma — what is the difference?
COPD causes irreversible airflow obstruction from chronic exposure to irritants (smoking), typically starting after age 40, with progressive daily symptoms and minimal variability. Asthma causes reversible obstruction from airway hyperreactivity, usually beginning in childhood, with episodic symptoms that vary considerably and often respond to allergens. Spirometry in COPD shows FEV₁/FVC <0.70 with <12% bronchodilator reversibility; asthma shows >12% and >200 mL improvement or normal spirometry between episodes. Some patients have features of both (asthma-COPD overlap).
Key drugs
Related conditions and differentials
Sources and further reading
StatPearls (NCBI Bookshelf)MedlinePlusWHO ICD-10: J44
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.